# BRAIN Biotech

其 BRAINBiocatalysts 板块提供工业用酶、微生物与配料，同时开展 CRO 业务与生产菌株开发，并已获得 CRISPR-BMC 核酸酶的欧洲专利（EP4301852 B1）。该核酸酶在细菌、酵母、真菌、植物与哺乳动物细胞等原核与真核生物中均具高活性，并明确面向 E. coli、Bacillus、Pichia、Aspergillus 等微生物生产菌株的优化。

Source: https://cn.bioecon.ru/companies/brain-biotech/
Updated: 2026-08-15

- 国家: Germany

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 营收 | €4960万(2024/25财年) | https://www.brain-biotech-group.com/en/investors/brain-biotech-ag-at-a-glance/, https://www.brain-biotech-group.com/en/news-media/press-releases/fy-202425-brain-biotech-ag/, https://www.brain-biotech.com/ecomaXL/files/2026-01-12_BRAIN_Biotech_GB_EN-FINAL.pdf, https://www.brain-biotech.com/ecomaXL/files/3M_Report_2025-26_EN_final_BRAIN_Biotech.pdf |
| 员工人数 | 约280名员工（截至2025年9月） | https://www.brain-biotech-group.com/en/investors/brain-biotech-ag-at-a-glance/, https://www.brain-biotech-group.com/en/news-media/press-releases/fy-202425-brain-biotech-ag/, https://www.brain-biotech.com/ecomaXL/files/2026-01-12_BRAIN_Biotech_GB_EN-FINAL.pdf, https://www.brain-biotech.com/ecomaXL/files/3M_Report_2025-26_EN_final_BRAIN_Biotech.pdf |
| 生产基地 | 德国茨温根贝格、德国波茨坦、英国卡迪夫、荷兰尼乌屈克、德国比特尔博恩、美国坦帕 | https://www.brain-biotech.com/en/faq/ |
| 产能 | 在卡迪夫设施将工艺放大至10立方米 | https://www.brain-biotech.com/en/news-events/news/methanol-free-komagataella-phaffii-pichia-pastoris-system-for-scalable-cost-effective-industrial-protein-production/ |
| 认证 | ISO 9001、ISO 14001、ISO 45001、FSSC 22000、犹太洁食、清真、SEDEX会员资格(因工厂而异) | https://www.brain-biotech-group.com/ecomaXL/files/Sustainability_Report_VSME_FY_2023-24.pdf |
| 监管批准 | 支持EFSA和FDA申报文件；符合食品/制药安全标准 | https://www.brain-biotech.com/en/faq/ |
| 融资 | 公共资助项目（EU、BMBF、BMWK、FFG）、研发税收抵免以及潜在的里程碑付款（例如来自 Akribion 的最高约 92M 欧元，来自 Pharvaris/Royalty Pharma 的约 138M 欧元） | https://seat11a.com/company/brain-biotech-ag-company-presentation/, https://www.brain-biotech.com/ecomaXL/files/3M_Report_2025-26_EN_final_BRAIN_Biotech.pdf |

独立来源: seat11a.com

## 技术

- [菌株工程（合成生物学 CRO）](https://cn.bioecon.ru/technology/strain-engineering-synbio-cro/)